EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 477 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR How I Found a Meaningful Career After Cancer October 26, 2020 Cleveland Clinic Launches Breast Cancer Vaccine Trial October 28, 2021 ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March March 14, 2025 Peer-to-peer match-funding initiative raises over £4 million for cancer research May 18, 2021 Load more HOT NEWS From athlete to wig-maker: how cancer changed Maria’s destiny Sugar and cancer – what you need to know Favourable Response More Likely with Neoadjuvant Dual Immune Checkpoint Inhibitor Than... How My Inherited Cancer Diagnosis Has Made Me a Better Oncologist
